Alan H. Bryce, MD

Alan H. Bryce, MD

City of Hope

Phoenix, Arizona

Alan H. Bryce, MD, is a medical oncologist and chief clinical officer at City of Hope in Phoenix, Arizona. Dr. Bryce holds an appointment as a professor with the Department of Medical Oncology & Therapeutics Research, with City of Hope, as well as an appointment as a professor of Molecular Medicine at Translational Genomics Research Institute (TGen), which is also part of City of Hope.

Prior to joining City of Hope, Dr. Bryce spent 12 years at the Mayo Clinic in Phoenix, where he served as chair of the Division of Hematology and Medical Oncology, as well as Director of the Mayo Clinic Arizona Comprehensive Cancer Center. Dr. Bryce received his medical degree from the Chicago Medical School, and then completed an internal medicine residency and a hematology and oncology fellowship at the Mayo Clinic in Rochester, Minnesota. During his time at Mayo, Dr. Bryce served as an international co-principal investigator on multiple clinical trials for prostate cancer, with his research focused on cancer genetics, novel therapies and immunotherapeutic approaches.

Disclosures:

Dr. Bryce has the following disclosures:
Consulting Fees: Astellas, Bayer, Novartis

Talks by Alan H. Bryce, MD

Universal Germline Screening in Prostate Cancer: The Argument Against

Posted by | Jan 2021

Alan H. Bryce, MD, Medical Director of the Genomic Oncology Clinic at Mayo Clinic in Scottsdale, Arizona, argues against universal germline screening in prostate cancer in a point-counterpoint debate. While he agrees that identifying germline mutations is important and can have important implications for therapy and for patients’ families, Dr. Bryce observes that very few carriers are identified through germline testing. Approximately ⅔ of carriers are identified through family history-based screening, and while germline mutations are more common in men with metastatic cancer, they are uncommon in the total prostate cancer population. This means that among low- and intermediate-risk patients, 200-300 people must be screened to find one additional carrier, and among high-risk patients, approximately 50 people must be screened to find an additional carrier. Genetic testing costs money and takes up valuable counseling time, so Dr. Bryce argues that testing all patients is not a sensible allocation of resources.

Read More
Updates in PARP Inhibition and Germline Testing in Prostate Cancer

Updates in PARP Inhibition and Germline Testing in Prostate Cancer

Posted by | Oct 2020

Alan H. Bryce, MD, Medical Director of the Genomic Oncology Clinic at Mayo Clinic Arizona in Scottsdale, outlines recent treatment updates for prostate cancer patients, beginning with a brief review of germline testing recommendations. Following this, Dr. Bryce discusses two newly-approved PARP inhibitors that target mutations: rucaparib and olaparib. Dr. Bryce then poses a series of questions and challenges that physicians should consider as ongoing trials for various disease states and combinations (neoadjuvant, metastatic castrate sensitive prostate cancer, firstline metastatic castrate resistance prostate cancner, PARP inhibition + immunotherapy, etc.) continue.

Read More
Genetics and Biomarkers for Prostate Cancer and Bladder Cancer

Genetics and Biomarkers for Prostate Cancer and Bladder Cancer

Posted by | Oct 2020

Alan H. Bryce, MD, Medical Director of the Genomic Oncology Clinic at Mayo Clinic Arizona in Scottsdale, discusses genetics and biomarkers for prostate cancer and bladder cancer. Genetic testing is now considered part of best practice for the treatment of cancer, but even still the topic can be confusing due to the number of different test types and scenarios. In order to combat this confusion, it is important that urologists continue to educate themselves on the matter. Dr. Bryce discusses the purpose of using either germline or somatic tests and the different information they can tell us. He goes into particular detail about the somatic test and how useful it can be in determining which targeted therapies to use for both prostate and bladder cancer. Finally, he also offers some advice on best practices for utilizing the somatic test including: testing every patient, always using a fresh biopsy, and retesting before each line of systemic therapy.

Read More
Genetic Testing and Next Generation DNA Sequencing in Prostate Cancer

Genetic Testing and Next Generation DNA Sequencing in Prostate Cancer

Posted by | Jul 2020

Alan H. Bryce, MD, Associate Professor of Medicine at the Mayo Clinic in Phoenix, Arizona, gives an update on how and why to use germline and somatic testing in prostate cancer. He discusses updated National Comprehensive Cancer Network and Society of Urologic Oncology guidelines on who should receive germline and somatic testing, and notes that approved somatic therapies, including PARP inhibitors for BRCA1 and 2 and immunotherapy for microsatellite instability-high tumors, are only available to patients who have tested positive for the relevant mutations, underscoring the importance of widespread testing. Dr. Bryce also emphasizes the importance of germline testing for the patient’s family members, since the knowledge that they carry a hereditary cancer risk gene may allow them to receive early, life-saving cancer diagnoses. The presentation concludes with a Q&A session with E. David Crawford, MD, Professor of Urology at the University of California, San Diego, during which Drs. Crawford and Bryce discuss the limitations of taking a family history and how reimbursement works for multiple genetic tests.

Read More
Point-Counterpoint: There is a Role for Currently Available Biomarkers/Genomics in the Risk Stratification of Prostate Cancer

Point-Counterpoint: There is a Role for Currently Available Biomarkers/Genomics in the Risk Stratification of Prostate Cancer

Posted by | May 2020

E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, and Alan H. Bryce, MD, Chair of the Division of Hematology and Medical Oncology and Assistant Professor of Medicine at the Mayo Clinic in Phoenix, Arizona, present a Point-Counterpoint on the relative value of genomics and biomarkers in prostate cancer risk stratification. Dr. Crawford, presenting the pro side, argues that doctors need to do biomarker testing to know which patients to biopsy, follow closely, and treat with radiation. Dr. Bryce, presenting the con side, contends that while germline testing is beneficial, other biomarker tests have inconsistent results for prostate cancer patients.

Read More

Join the GRU Community

- Why Join? -